Company profile

iOnctura

Privately held: no public share price (Geneva-based clinical-stage oncology biotech; privately funded, €80M Series B led by Syncona in 2024. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.cancerresearchhorizons.com/news/ionctura-announces-eu80m-series-b-financing-progress-pipeline-through-phase-2-trials]) · Switzerland

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
IOA-244
Phase 2
PI3K-deltaSmall molecule
Non-Small Cell Lung Cancer
roginolisib
Phase 2
PI3K-deltaSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.